Ozanimod not checked
Celgene · BMS-986374 · RPC1063
FollowEvery change as it happens, and a Monday email
Trials
5 active
26 in total · 8 in the EU
What this is
- How it works
- Sphingosine 1-phosphate Receptor Modulator FDA class
- Tested for
- Relapsing Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Colitis, Ulcerative
- Main trialPhase 4
- “The purpose of this study is to assess the effectiveness and safety of ozanimod in Chinese adults with relapsing multiple sclerosis.”In the company’s words, NCT06396039 on ClinicalTrials.gov
- Other names
- BMS-986374 · RPC1063 · Zeposia · RPC-1063 · RPC 1063
Other drugs for Relapsing Multiple Sclerosis
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- FrexalimabSanofi · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
Coming up3
- 29 Dec 2028Phase 4 trial completes · ClinicalTrials.gov
- 11 Apr 2031Phase 3 trial completes · ClinicalTrials.gov
- 12 Jul 2032Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 29 Dec 2028 | A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis | |
| Phase 3Recruiting | 11 Apr 2031 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | |
| Phase 2/3Recruiting | 12 Jul 2032 | A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis | |
| Phase 4Terminated | 21 Jan 2025 | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | |
| Phase 3Completed | 27 Mar 2017 | Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis | |
| Phase 3Completed | 27 Mar 2020 | Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis | |
| Phase 3Completed | 5 Jan 2023 | A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | |
| Phase 3Completed | 21 Nov 2023 | Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | |
| Phase 3Terminated | 1 Oct 2024 | Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | |
| Phase 3Terminated | 3 Oct 2024 | A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease | |
| Phase 3Terminated | 31 Oct 2024 | An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease | |
| Phase 3Completed | 19 Dec 2024 | An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | |
| Phase 3Terminated | 7 Mar 2025 | A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) | |
| Phase 3Terminated | 15 May 2025 | Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) | |
| Phase 3Completed | 30 Sep 2025 | To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2/3Completed | 13 Apr 2014 | Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients | |
| Phase 2/3Terminated | 13 Sep 2024 | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy | |
| Phase 2Completed | 10 Mar 2015 | Efficacy and Safety Study of Ozanimod in Ulcerative Colitis | |
| Phase 2Completed | 12 Sep 2019 | Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease | |
| Phase 1Completed | 26 Sep 2020 | A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects | |
| Phase 1Completed | 19 May 2021 | A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects | |
| Phase 1Completed | 17 Sep 2021 | Taste Assessment of Ozanimod | |
| Phase 1Completed | 6 Apr 2022 | A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod | |
| Phase 1Completed | 26 Feb 2023 | Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants | |
| Phase 4Authorised | not given | Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsingremitting multiple sclerosis: correlation with disease activity, cognition, fatigue,depression and quality of life | |
| Phase 4Authorised | not given | Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study PROTOCOL CODE: OZA22 / IM047 - 048 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026